On the basis of the benefits of frontline radiation in early-stage, extranodal natural killer (NK)/ @entity784 (ENKTL), we conducted the trial of concurrent chemoradiotherapy (CCRT) followed by three cycles of @entity136 , @entity619 and @entity900 ( @entity3006 ). Thirty-two @entity1 with newly diagnosed, stage IE to IIE, nasal ENKTL received CCRT (that is, all @entity1 received intensity-modulated radiotherapy 56 Gy and @entity900 30 mg/m(2) weekly, 3-5 weeks). Three cycles of @entity3006 ( @entity136 1000 mg/m(2) intravenously (i.v.) on days 1 and 8, @entity619 40 mg orally on days 1-4 and @entity900 75 mg/m(2) i.v. on day 1 ( @entity3006 ), every 21 days as an outpatient were scheduled after CCRT. All @entity1 completed CCRT, which resulted in 100% response that included 24 complete responses (CRs) and eight partial responses. The CR rate after CCRT was 75.0% (that is, 24 of 32 responses). Twenty-eight of the 32 @entity1 completed the planned three cycles of @entity3006 , whereas four @entity1 did not because they withdrew (n = 1) or because they had an @entity281 (n = 3). The overall response rate and the CR rate were 90.6% (that is, 29 of 32 responses) and 84.4% (that is, 27 of 32 responses), respectively. Only two @entity1 experienced grade 3 @entity137 during CCRT ( @entity390 ), whereas 13 of the 30 @entity1 experienced grade 4 @entity1398 . The estimated 3-year overall survival and progression-free rates were 87.50% and 84.38%, respectively. In conclusion, CCRT followed by @entity3006 chemotherapy can be a feasible and effective treatment strategy for stage IE to IIE nasal ENKTL.

Concurrent IMRT and weekly @entity900 followed by XXXX chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/ @entity784 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity784 :: ('MESH:D016399', 'Disease') :: ['T-cell lymphoma'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity3006 :: ('MESH:D006153', 'Chemical') :: ['GDP'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']
@entity3006 :: (MESH:D006153,Chemical) :: ['GDP']
